Project Grant HT94252310619
Award Date
8/1/23
Completion Date
7/31/26
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) provides $1,235,845.00 to the University of Illinois to leverage data science methods and deliver individualized treatment effects in metastatic hormone sensitive prostate cancer. The 3-year project, with a performance period from August 15, 2025 to August 14, 2028, aims to advance disease prevention, diagnosis, treatment, and management through basic,...
The University of Illinois received a $690,539 project grant award from the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 through July 31, 2026 to investigate G0S2 as a master regulator of the local estrogenic environment during breast cancer progression and antiestrogen therapy. Through this award, the University will conduct scientific research that aims to transform healthcare for service...
The Defense Health Agency awarded a $159,892 Project Grant to the University of Illinois under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into "Metabolic Vulnerabilities Associated to G12C Inhibitor Resistance" from January 1, 2022 through December 31, 2023. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award will...
This $159,811 federal Project Grant awarded on May 1, 2024 by the Defense Health Agency supports research at the University of Illinois to investigate the role of SOX4 in phenotypic transformation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) in order to overcome acquired drug resistance. The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military...
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,602,572.00 in funding to the University of Illinois to support research on the role of the novel hexokinase HKDC1 in hepatocellular carcinoma. The award has a performance period from July 15, 2024 to July 14, 2027. The University of Illinois, a major public research university in Chicago, will conduct innovative scientific studies to advance...
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
The University of Illinois was awarded a $798,912 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate how PFAS (per- and polyfluoroalkyl substances) exposures can reprogram prostate stem cells and drive carcinogenesis and cancer progression. The 3-year project, running from July 1, 2023 to June 30, 2026, will advance scientific understanding of how environmental PFAS exposures may...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
The federal Project Grant award of $312,610.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The purpose of the award is to support research on the "ROLE OF FUNCTIONAL FACTORS IN AR REPROGRAMMING AND PROGRESSION OF PROSTATE CANCER". The award was made to Weill Medical College of Cornell University, a prominent academic medical institution, on September 30, 2024, with a performance period ending on September 29,...
This $1,124,825 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to identify novel therapeutic targets for aggressive prostate cancer through induced pluripotent stem cell modeling of BRCA2 mutant prostate tissue. The award, which runs from August 1, 2024 to July 31, 2027, will enable UTHSCSA to conduct innovative scientific...